| 0.249 -0.037 (-12.88%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.45 |
1-year : | 0.56 |
| Resists | First : | 0.39 |
Second : | 0.48 |
| Pivot price | 0.29 |
|||
| Supports | First : | 0.24 |
Second : | 0.2 |
| MAs | MA(5) : | 0.27 |
MA(20) : | 0.29 |
| MA(100) : | 0.3 |
MA(250) : | 0.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 7.1  |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 1.14 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ITOC ] has closed below the lower bollinger band by 5.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ITOC ] is to continue within current trading range. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.24 - 0.24 | 0.24 - 0.25 |
| Close: | 0.25 - 0.25 | 0.25 - 0.25 |
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Fri, 02 Oct 2026
iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026 - GlobeNewswire
Mon, 28 Sep 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Fri, 25 Sep 2026
ITOC Shareholders Have Opportunity to Lead iTonic Holdings Ltd. f - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 9 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 102 (K) |
| Shares Short P.Month | 133 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | -682 % |
| Return on Assets (ttm) | -41 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 91.5 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 4.46 |
| Price to Cash Flow | -0.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|